ASCO 2017 | Avelumab in Merkel Cell Carcinoma – updates from ASCO 2017
Dr Sandra D’Angelo from Memorial Sloan Kettering Cancer Center, New York, gives us an update on the use of avelumab as frontline therapy for patients with Merkel cell carcinoma during ASCO 2017. She describes some of the excitement and experience using immunotherapy in these patients. One year on from initial data presented on avelumab we are learning a lot but further study is warranted as it’s still early days.
Get great new content delivered to your inboxSign up